Recombinant FDPS/Farnesyl Diphosphate Synthase Monoclonal Antibody (AN300076P)
For research use only.
| Verified Samples |
Verified Samples in WB: HepG2, Hela Verified Samples in FCM: HeLa Verified Samples in IF: HUVEC |
| Dilution | WB 1:500-1:2000, FCM 1:25-1:100, ICC/IF 1:20-1:100, IP 1-4 μL/mg of lysate |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB, FCM, ICC/IF, IP |
| Clonality | Rabbit Monoclonal |
| Immunogen | Recombinant Human FDPS / Farnesyl Diphosphate Synthase protein |
| Abbre | FDPS |
| Synonyms | KIAA, POROK, FDPS, FPPS, FPS, POROK9, Dimethylallyltranstransferase, Farnesyl diphosphate synthase, Farnesyl diphosphate synthetase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthetase, FPP synthase, FPP synthetase, FPPS_HUMAN, Geranyltranstransferase, KIAA1293 |
| Swissprot | |
| Calculated MW | 48 kDa |
| Observed MW |
38 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Concentration | 1 mg/mL |
| Buffer | 0.2 μm filtered solution in PBS |
| Purification Method | Protein A |
| Research Areas | Cardiovascular, Signal Transduction, Cancer, Metabolism |
| Clone No. | 11D13 |
| Conjugation | Unconjugated |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Shipping | Ice bag |
| background | This gene encodes an enzyme that catalyzes the production of geranyl pyrophosphate and farnesyl pyrophosphate from isopentenyl pyrophosphate and dimethylallyl pyrophosphate. The resulting product, farnesyl pyrophosphate, is a key intermediate in cholesterol and sterol biosynthesis, a substrate for protein farnesylation and geranylgeranylation, and a ligand or agonist for certain hormone receptors and growth receptors. Drugs that inhibit this enzyme prevent the post-translational modifications of small GTPases and have been used to treat diseases related to bone resorption. Multiple pseudogenes have been found on chromosomes 1, 7, 14, 15, 18 and X. Multiple transcript variants encoding different isoforms have been found for this gene. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
